Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Perry

Vascular Surgery North Dartmouth, MA Medical Doctor

NPI 1285997734 CMS profile 239573

300A Faunce Corner Rd, North Dartmouth, MA 02747

Open in the dashboard

General payments

$6,005

118 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Perry of North Dartmouth, MA is reported in the CMS Open Payments database as having received $6,005 across 118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,118 22
2024 General $417 13
2023 General $972 16
2022 General $1,171 30
2021 General $896 18
2020 General $224 6
2019 General $1,208 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Perry
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mark Perry were reported at $1,118. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mark Perry Vascular Surgery median Middle half National median
2019 $1,208 $796 $226–$2,363 $163
2020 $224 $348 $118–$1,110 $114
2021 $896 $471 $158–$1,421 $132
2022 $1,171 $725 $222–$2,183 $149
2023 $972 $836 $257–$2,440 $160
2024 $417 $909 $252–$2,619 $164
2025 $1,118 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $1,214 10 payments
  2. Medtronic, Inc. $934 13 payments
  3. Abbott Laboratories $506 27 payments
  4. Endologix, Inc. $496 9 payments
  5. Cardiovascular Systems Inc. $419 3 payments
  6. Boston Scientific Corporation $414 9 payments
  7. Penumbra, Inc. $348 3 payments
  8. Bolton Medical Inc $276 2 payments
  9. Shockwave Medical, Inc $264 11 payments
  10. W. L. Gore & Associates, Inc. $254 4 payments
  11. Other $882 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,202 111 payments
  2. Travel and Lodging $715 5 payments
  3. Education $88 2 payments
Products named General payments · program years 2019–2025
  1. ENROUTE 0.014 Guidewire $1,003 8 payments
  2. ENROUTE Transcarotid Stent System $1,003 8 payments
  3. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $1,003 8 payments
  4. ENHANCE Transcarotid Peripheral Access Kit $1,003 8 payments
  5. ENDURANT IIS $713 7 payments
  6. Diamondback Peripheral $419 3 payments
  7. Indigo System $348 3 payments
  8. TREO ABDOMINAL STENT-GRAFT SYSTEM $276 2 payments
  9. ENROUTE Transcarotid Neuroprotection System Enroute Nps 2.5 Plus - Pi $233 1 payment
  10. ENROUTE Transcarotid Stent $211 2 payments
  11. Other $2,913 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

530

Median for Vascular Surgery: 122

Drug cost

$117,595

Median for Vascular Surgery: $14,135

Branded share of claims

64.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 96 $71,480
Xarelto Rivaroxaban Brand 48 $29,892
Brilinta Ticagrelor Brand 24 $11,633
Clopidogrel Clopidogrel Bisulfate Brand 172 $1,895
Cilostazol Generic 89 $1,825
Pantoprazole Sodium Generic 24 $355
Gabapentin Generic 22 $258
Oxycodone Hcl Generic 21 $125
Atorvastatin Calcium Generic 16 $80
Amoxicillin Generic 18 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 134 billing codes

Paid by Medicare

$383,184

Medicare's payments for the services billed

Medicare patients

814

Average age 74

Services billed

2,870

423 women, 391 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 49%
Diabetes 44%
Chronic kidney disease 42%
Heart failure 34%
COPD 33%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record